Dan said::"Who cares what reporters said. Journalists and are not held to the same standard of reporting as a publically traded company. Matrixx said that the FDA is not investigating Zicam Cold Remedy. The only question is whether the journalists are playing games with semantics, were misled by someone (maybe a short seller that fed them incorrect or misleading information for their article), or lying outright."
=================================================
FDA SAID ACCORDING TO DOW JONES:"Commenting on a statement by Matrixx on Feb.2 that it wasn't aware of an FDA inquiry, FDA's spokesman Brad Stone said "if the company wasn't aware that we are looking into this matter, it should be aware of it at this point...It's a matter of public record that we are looking into it."
sg.biz.yahoo.com
Wednesday February 18, 2:29 AM
Matrixx Has Contacted FDA About Zicam Cold Remedy
By Carol S. Remond
Of Dow Jones Newswires
NEW YORK (Dow Jones)--Matrixx Initiatives Inc. (MTXX) says that it will cooperate with the Food and Drug Administration and answer any questions that the government agency may have about the safety of Zicam Cold Remedy.
Get your lucky numbers every on Sunday and Wednesday!
My Mobile No.
Matrixx Chief Executive Officer Carl Johnson told investors during a conference call Tuesday that the company has not "been informed by the FDA of an inquiry or an investigation."
Johnson said reports linking Zicam Cold Remedy to anosmia, or loss of smell, are "misleading and completely unfounded."
"However, reflecting our concern for this issue, we have taken the unusual step of communicating with the FDA, providing them with copies of our public statements on this matter. And we assured them that we will cooperate openly and fully should they have any questions what so ever regarding this matter," Johnson said.
Dow Jones first reported on Jan. 30 in an "In The Money" column that the FDA is looking into complaints that Zicam Cold Remedy, a spray designed to deliver a zinc gel into the nose, may be causing some users to lose their sense of smell. Other news organizations have since reported similar stories.
So far, five lawsuits have been filed against Matrixx by users of Zicam Cold Remedy who claim to have lost their sense of smell after using the product.
An FDA spokeperson wasn't immdiately available to comment on Johnson's statements.
Commenting on a statement by Matrixx on Feb.2 that it wasn't aware of an FDA inquiry, FDA's spokesman Brad Stone said "if the company wasn't aware that we are looking into this matter, it should be aware of it at this point...It's a matter of public record that we are looking into it."
The company's stock is currently trading at $10.59, up 39 cents or 3.8%, on volume of 315,531 shares.
--------------------------------------------------------------------------------
Copyright © 2004Dow Jones & Company Inc. All rights reserved. |
